Veeva

ARTICLE

Are These 5 Misconceptions Keeping You From Modernizing QC?

Lab capabilities are advancing fast, but progress could be undermined by legacy QC technology infrastructure.

Biopharma organizations have to balance competing forces as they approach commercialization. From the early stages of drug development, their teams must be ready to scale their activities efficiently without adding cost or slowing time to market. However, scientific advances in new modalities mean products are more complex and costly to manufacture and test. Given the increasing regulatory scrutiny of virtual biotech, even sponsor companies outsourcing these activities must efficiently scale their external partner and quality control (QC) oversight.

To operate effectively, most companies strive to end their teams' reliance on paper-based processes and introduce better data management. Yet addressing specific QC challenges one at a time often leads to a collection of point solutions, each with its own set of problems.

Some systems are difficult to maintain or connect with existing technology; others are not user-friendly. The impact is that QC staff are forced to duplicate their data entry and navigate multiple disjointed systems to execute a single work process. Some might default to paper-based activities to compensate, which undermines operational efficiency and inspection readiness.